Q-omics provides the consensus-scored LGALS9DP profile across patient tissues and cancer cell-line models. LGALS9DP expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LGALS9DP is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, LGALS9DP RNA expression shows 8,968 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, KIRC, and DLBC as cancer lineages where LGALS9DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGALS9DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGALS9DP survival associations across molecular data types. LGALS9DP RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGALS9DP RNA expression–survival associations across cancer types. High LGALS9DP expression shows unfavorable associations in LIHC and LGG, but favorable associations in BLCA, ESCA, SKCM and SARC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LGALS9DP RNA expression.
This table summarizes LGALS9DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LGALS9DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGALS9DP shows higher tumor expression in KIRC, STAD, LIHC and THCA. The KIRC box plot shows higher LGALS9DP RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p < 0.001).
This table shows molecular features associated with LGALS9DP in patient tissues and cancer cell lines. In patient samples, LGALS9DP shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
